The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis28 May 2010 • by Natalie Aster
GBI Research’s latest report, “The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis”, essentially provides insights on the monoclonal antibodies market potential, actual sales, actual volume and price forecasts till 2015. The report also delves deep into the monoclonal antibodies market potential in various indications such as rheumatoid arthritis and metastatic NSCLC. In addition, the report provides insights into the monoclonal antibodies R&D pipeline and the potential blockbusters. The report also elucidates monoclonal antibodies competitive landscape including benchmarking of leading companies. Finally, key trend analysis on mergers and acquisitions and licensing agreements involving monoclonal antibodies are also provided.
Rapid Uptake of Monoclonal Antibodies Coupled with Expanded Indications are the Key Drivers for the Growth of the Monoclonal Antibodies Market
The global monoclonal antibodies market was valued at $27.4 billion in 2008, indicating a Compound Annual Growth Rate (CAGR) of 30.8% between 2000 and 2008. The growth in sales is primarily driven by rapid uptake of monoclonal antibodies, expansion of patient base due to the drug approvals received, and no generics for biological therapies. By 2015, due to the expected launch of many new therapies such as Denosumab and Teplizumab, the sales of monoclonal antibodies is expected to reach $67.6 billion, indicating a CAGR of 13.8% between 2008 and 2015.
In 2008-09, 193 Monoclonal Antibodies were in Pipeline with a Majority Being Tested for Various Cancer Indications
In 2008-09, 193 monoclonal antibodies were under research and development. Approximately, 375 clinical trials are under process for these 193 monoclonal antibodies. Maximum number of clinical trials is being conducted for various cancer indications. In 2008, cancer accounted for 63.2% of the total clinical trials in process on monoclonal antibodies. Autoimmune diseases accounted for 12.5% of the total clinical trials conducted on monoclonal antibodies.
High Growth Potential in Diseases Associated with Genetic Mutations such as Oncology, Autoimmune Diseases and Organ Transplantations
The total market potential for monoclonal antibodies was estimated at $45.9 billion in 2008. Oncology accounted for 53.8% of the total market potential while autoimmune diseases accounted for 37.3%. The rest of the share was accounted by infectious diseases and organ transplantation. Therapeutic applications of monoclonal antibodies are extending to new therapy areas such as CNS disorders and metabolic disorders. Nevertheless, by 2015, oncology and autoimmune diseases will still account for 90% of the monoclonal antibody market.
The M&A Landscape of Monoclonal Antibodies Market is Very Attractive Driven by Heavy Funding by Venture Capitalists and Large Pharmaceutical Companies
GBI Research identifies that mergers and acquisitions (M&A) and licensing agreements are very active in the monoclonal antibodies market. The monoclonal antibodies market is inundated by heavy venture capitalist funding on SME biotechnology companies developing monoclonal antibodies. In addition, large pharmaceutical companies are acquiring SME biotech companies having promising monoclonal antibodies in late-stage development. In addition, large companies such as Pfizer and Johnson & Johnson are encouraging collaboration agreements, with institutes and small biotech companies, to develop promising monoclonal antibodies. As a result, the total M&A landscape of the monoclonal antibodies market in 2008-09 was valued at approximately $8 billion.
Roche/Genentech, Abbott and Johnson & Johnson Lead the Monoclonal Antibodies Market in 2008
In 2008, Roche/Genentech was the leading company in the monoclonal antibodies market with sales worth $16.5 billion, accounting for a market share of 49.6%. Abbott generated sales worth $4.8 billion accounting for an approximate market share of 14.5% while Johnson & Johnson generated sales worth $3.7billion accounting for an approximate share of 11.2%.
GBI Research forecasts more M&A activity at least for the next four to five years as many new players are expected to enter into the monoclonal antibodies market.
About GBI Research
GBI Research is a leading business information company providing global business information reports and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.